Evidence map›Paper›PMID 38390278›Full record

ArticleFrontiers in pediatrics2024

A case report of a child with pulmonary hypertension associated with SARS-CoV-2 infection.

Kentaro Okunushi, Hironobu Kobayashi, Yuri Yoh, Masaya Kunimatsu, Tadashi Shiohama, Tomozumi Takatani, Hiromichi Hamada

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kentaro OkunushiDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hironobu KobayashiDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Yuri YohDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Masaya KunimatsuDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tadashi ShiohamaDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Tomozumi TakataniDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Hiromichi HamadaDepartment of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Chiba University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We encountered a pediatric case of pulmonary hypertension triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 14-year-old girl was brought to the emergency department of our hospital with fever, respiratory distress, and impaired consciousness. She tested positive for SARS-CoV-2 upon a polymerase chain reaction examination and had prolonged hypoxemia without pneumonia. An echocardiography revealed elevated right ventricular pressure. She was diagnosed with pilocytic astrocytoma at the age of 10 years and underwent a resection of a pituitary tumor. Hormone replacement therapy was administered postoperatively, but her growth hormones were not activated because of concerns about tumor recurrence. Echocardiography at the age of 13 years showed normal right ventricular pressure. On admission, she had an abnormal liver function, elevated liver fibrosis markers, a decreased platelet count, and hepatosplenomegaly, suggesting pulmonary and portal hypertension. The diagnosis was pulmonary hypertension associated with SARS-CoV-2 infection. The mechanism of the pulmonary hypertension was thought to be portal hypertension owing to growth hormone deficiency and SARS-CoV-2 infection. The patient's symptoms improved with oxygenation and bed rest without additional targeted pulmonary hypertension therapy, and her right ventricular pressure decreased. This case demonstrates that a pediatric patient with subclinical pulmonary hypertension may develop pulmonary hypertension triggered by SARS-CoV-2 infection.

Indexed as

childrengrowth hormonepanhypopituitarismportal hypertensionpulmonary hypertensionSARS-CoV-2

Identifiers

PMID38390278
PMCPMC10881764
OpenAlexW4391648335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.